as 09-06-2024 4:00pm EST
Stocks
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.
Founded: | 2011 | Country: | Canada |
Employees: | N/A | City: | N/A |
Market Cap: | 90.8M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 4.3K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.92 | EPS Growth: | N/A |
52 Week Low/High: | $2.39 - $3.50 | Next Earning Date: | 01-01-0001 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
EPRX Breaking Stock News: Dive into EPRX Ticker-Specific Updates for Smart Investing
CNW Group
4 days ago
PR Newswire
a month ago
CNW Group
a month ago
CNW Group
a month ago
PR Newswire
2 months ago
CNW Group
2 months ago
CNW Group
2 months ago
GuruFocus.com
3 months ago
The information presented on this page, "EPRX EUPRAXIA PHARMACEUTICALS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.